On 11 September 2026, Sky News published an undercover investigation into the online trade in unregulated peptides. A reporter bought products sold through social-media storefronts, sent them to a laboratory at the University of Manchester for analysis, and set the results alongside interviews with users, clinicians and academics. The findings sit at the centre of a regulatory question the UK has not yet settled: when is a peptide sold as "for research use only" actually a medicine in law?

What the investigation did

The reporter, Katie Templeton-Knight, bought unregulated peptides from sellers advertising on social media, including a copper-binding peptide marketed with a purity claim of 99%. One product, ordered as BPC-157, arrived without cold-chain packing despite the seller's instruction to refrigerate it on receipt. The products were then sent to the University of Manchester for analysis.

What the laboratory reported

The Manchester analysis found the copper-binding peptide to be approximately 10% pure against the 99% claim on the seller's site. The laboratory attributed the balance to synthetic impurities and degradation products, and said that because the peptides had not been held in a laboratory freezer the material had broken down. These are single-sample findings: they characterise the products Sky bought, not the category as a whole.

The "research use only" question

The BBC reported the same week that Dr Luke Turnock of the University of Lincoln described the availability of peptides online as one of his main concerns, and called for the 'research use only' loophole to be tightened. The MHRA's stated position is that it determines whether a product is a medicine on a case-by-case basis.

Why the legal test is fact-specific

Under the Medicines Act 1968 and the Human Medicines Regulations 2012, a product is a medicinal product either by presentation or by function. A "not for human consumption" label does not, on its own, take a product outside that definition.

A fragmented enforcement picture

Responsibility is spread across the MHRA, the Advertising Standards Authority, the Competition and Markets Authority, Trading Standards and Ofcom, with platforms setting their own policies on top.

What this does and does not mean

  • It does not mean every research peptide sold in the UK is impure, nor that any particular vendor's products are.
  • It does not change the legal status of any compound.
  • It does not establish a therapeutic claim in either direction.

Peptide Data's position is unchanged. This is a research-reference publication; nothing here is consumption advice, and none of the compounds discussed are approved for human use.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.